Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Intangibles (2016 - 2026)

Ekso Bionics Holdings has reported Intangibles over the past 9 years, most recently at $5.2 million for Q4 2025.

  • On a quarterly basis, Intangibles rose 13.97% to $5.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.2 million, a 13.97% increase, with the full-year FY2025 number at $5.2 million, up 13.97% from a year prior.
  • Intangibles reached $5.2 million in Q4 2025 per EKSO's latest filing, up from $4.2 million in the prior quarter.
  • The five-year high for Intangibles was $5.2 million in Q2 2022, with the low at $4.2 million in Q3 2025.
  • The 4-year median for Intangibles is $5.2 million (2022), against an average of $5.0 million.
  • The largest YoY upside for Intangibles was 13.97% in 2025 against a maximum downside of 20.46% in 2025.
  • Tracing EKSO's Intangibles over 4 years: stood at $5.2 million in 2022, then increased by 0.44% to $5.2 million in 2023, then decreased by 12.6% to $4.6 million in 2024, then grew by 13.97% to $5.2 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $5.2 million, $4.2 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.